A tumor-targeting bacterial system based on Escherichia coli Nissle, which can reprogram tumor mechanisms and enhance immunotherapeutic efficacy through the release of cytolysin A (ClyA)-hyaluronidase (Hy) by OMVs, has been developed (Thomas et al., 2022). The gene discussed is KDM5D; the disease is neoplasm.